摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R)-2-(2-bromo-5-fluorophenoxy)propan-1-ol | 874336-08-0

中文名称
——
中文别名
——
英文名称
(2R)-2-(2-bromo-5-fluorophenoxy)propan-1-ol
英文别名
——
(2R)-2-(2-bromo-5-fluorophenoxy)propan-1-ol化学式
CAS
874336-08-0
化学式
C9H10BrFO2
mdl
——
分子量
249.08
InChiKey
FHZPSAWKIYTAMV-ZCFIWIBFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    287.6±25.0 °C(Predicted)
  • 密度:
    1.512±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:096afc7114de9751bd159239f681781a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2R)-2-(2-bromo-5-fluorophenoxy)propan-1-olplatinum(IV) oxidecopper(l) iodide二(氰基苯)二氯化钯三丁基膦氢气三乙胺 作用下, 以 乙醇乙腈 为溶剂, 生成 2-(3,5-dimethoxyphenyl)propan-2-yl (R)-(3-(4-fluoro-2-((1-hydroxypropan-2-yl)oxy)phenyl)propyl)carbamate
    参考文献:
    名称:
    Macrocyclic Modulators of the Ghrelin Receptor
    摘要:
    本发明提供了一种新颖的构象定义明确的大环化合物,已经证明是生长激素分泌素受体(GHS-R1a及其亚型、异构体和变体)的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂,用于治疗和预防一系列医疗状况,包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
    公开号:
    US20180110824A1
  • 作为产物:
    参考文献:
    名称:
    Macrocyclic Modulators of the Ghrelin Receptor
    摘要:
    本发明提供了一种新颖的构象定义明确的大环化合物,已经证明是生长激素分泌素受体(GHS-R1a及其亚型、异构体和变体)的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂,用于治疗和预防一系列医疗状况,包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
    公开号:
    US20180110824A1
点击查看最新优质反应信息

文献信息

  • Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
    申请人:Hoveyda Hamid R.
    公开号:US20110105389A1
    公开(公告)日:2011-05-05
    The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.
    本发明提供了新型构象定义的大环化合物,已被证明是生长激素分泌素受体(GRLN,生长激素分泌素受体,GHS-R1a及其亚型、异构体和/或变种)的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的拮抗剂或逆向激动剂,以及用于治疗和预防一系列医学疾病,包括但不限于代谢和/或内分泌紊乱、肥胖和与肥胖相关的疾病、食欲或进食紊乱、成瘾紊乱、心血管疾病、胃肠道疾病、遗传疾病、过度增殖性疾病、中枢神经系统疾病和炎症性疾病。
  • MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR
    申请人:TRANZYME PHARMA INC.
    公开号:US20130211045A1
    公开(公告)日:2013-08-15
    The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    本发明提供了一种新型构象定义的大环化合物,已经被证明是生长激素分泌肽受体(GHS-R1a和其亚型、同工异构体和变异体)的选择性调节剂。本文还描述了合成这些新化合物的方法。这些化合物可用作生长激素分泌肽受体的激动剂,以及用于治疗和预防一系列医学疾病,包括但不限于代谢和/或内分泌紊乱、胃肠道疾病、心血管疾病、肥胖和肥胖相关疾病、中枢神经系统疾病、遗传疾病、过度增生性疾病和炎症性疾病。
  • Methods of using macrocyclic modulators of the ghrelin receptor
    申请人:Fraser L. Graeme
    公开号:US20070021331A1
    公开(公告)日:2007-01-25
    The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
  • METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR
    申请人:Fraser Graeme L.
    公开号:US20090170757A1
    公开(公告)日:2009-07-02
    The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
  • US7491695B2
    申请人:——
    公开号:US7491695B2
    公开(公告)日:2009-02-17
查看更多